Intratumoral heterogeneity of HER2/neu in breast cancer - A rare event

Breast Journal

Volumn 13, Issue 2, 2007, Pages 122-129

  Hanna, Wedad ^a   Nofech Mozes, Sharon ^a   Kahn, Harriette J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Breast cancer; CISH; FISH; HER2 neu; Heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER INVASION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENES, ERBB-2; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2;

EID: 33847165329     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00396.x     Document Type: Article

References (53)

1. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
2. Perin T, Canzonieri V, Massarut S, et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 1996;32A:1148-55.
3. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study. Pathology 2004;36:221-29.
4. Ringberg A, Idvall I, Ferno M, et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol 2000;26:444-51.
5. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br J Cancer 2001;85:869-74.
6. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6:109-18.
7. Bijker N, Peterse JL, Duchateau L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-44.
8. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
9. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001;37(Suppl. 1):S3-S10.
10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
11. Shak S. Overview of the trastuzumab (herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26(4 Suppl. 12):71-77.
12. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
13. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
14. Ring A, Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin Breast Cancer 2003;4(Suppl. 1):S34-S41.
15. Hanna W. Testing for HER2 status. Oncology 2001;61(Suppl. 2):22-30.
16. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-82.
17. Hanna W, O'Malley F. Update of HER2/neu; predictive and prognostic value and testing recommendaions. Curr Oncol 2001;9(Suppl. 1):S18-S20.
18. Hanna W, Kwok K. Correlation of HER2/Neu testing using chromogenic in situ hybridization (CISH) with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast cancer. Mod Pathol. 2005;18(Suppl 1): 35A.
19. Lal P, Salazar PA, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004;121:631-36.
20. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 2003;100:3547-9.
21. Anderson GR, Stoler DL, Brenner BM. Cancer: the evolved consequence of a destabilized genome. Bioessays 2001;23:1037-46.
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-88.
23. Cardoso F, Di LA, Larsimont D, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12:615-20.
24. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-46.
25. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61:5345-48.
26. Briffod M, Hacene K, Le DV. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 2000;13:841-50.
27. Shimizu C, Fukutomi T, Tsuda H, et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20.
28. Varga Z, Caduff R, Pestalozzi B. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005;446:136-41.
29. Edgerton SM, Moore D, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-21.
30. De la Haba-Rodriguez JR, Ruiz BM, Gomez EA, et al. Comparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location. Cancer Invest 2004;22:219-24.
31. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-26.
32. Corzo C, Tusquets I, Suarez M, et al. Intratumoral heterogeneity of HER2/neu and topoisomerase IIalpha in breast cancer: a case with clonal monosomy 17. Cancer Genet Cytogenet 2004;154:89-90.
33. Glockner S, Buurman H, Kleeberger W, Lehmann U, Kreipe H. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-26.
34. Kobayashi M, Ooi A, Oda Y, Nakanishi I. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol 2002;33:21-28.
35. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001;14:677-85.
36. Hanna W, Kwok K. Chromogenic in situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481-87.
37. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15:657-65.
38. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004;10:4793-98.
39. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
40. Shen CY, Yu JC, Lo YL, et al. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000;60:3884-92.
41. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-97.
42. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124:273-81.
43. Adem C, Soderberg CL, Hafner K, et al. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 2004;41:1-11.
44. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995;26:210-16.
45. Frierson HF Jr. Ploidy analysis and S-phase fraction determination by flow cytometry of invasive adenocarcinomas of the breast. Am J Surg Pathol 1991;15:358-67.
46. Meyer JS, Wittliff JL. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int J Cancer 1991;47:213-20.
47. Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol 2004;30:251-56.
48. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004;11:497-522.
49. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-50.
50. Kittiniyom K, Gorse KM, Dalbegue F, Lichy JH, Taubenberger JK, Newsham IF. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res 2001;3:192-98.
51. Heim S, Teixeira MR, Dietrich CU, Pandis N. Cytogenetic polyclonality in tumors of the breast. Cancer Genet Cytogenet 1997;95:16-19.
52. McClelland RA, Barrow D, Madden TA, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142:2776-88.
53. Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-51.